Atlas Venture

Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells to address various diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020 and based in Cambridge, Massachusetts, the company aims to overcome significant challenges associated with traditional cell and gene therapies, such as the limitations of dosing, unpredictable reactions in patients, and the necessity of pre-treatment chemotherapy. By leveraging precision genome editing, Be Biopharma creates durable and effective cell therapies that can be administered without toxic conditioning, thereby improving treatment options for conditions like Hemophilia B and enhancing overall patient outcomes.

Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells to address various diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020 and based in Cambridge, Massachusetts, the company aims to overcome significant challenges associated with traditional cell and gene therapies, such as the limitations of dosing, unpredictable reactions in patients, and the necessity of pre-treatment chemotherapy. By leveraging precision genome editing, Be Biopharma creates durable and effective cell therapies that can be administered without toxic conditioning, thereby improving treatment options for conditions like Hemophilia B and enhancing overall patient outcomes.

Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.

Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies that target RNA processing to address various diseases. Established in 2018 and based in Cambridge, Massachusetts, the company employs its proprietary biology platform to identify and prioritize therapeutic targets within RNA processing. Through its REMseq platform, Remix Therapeutics validates potential drug targets and optimizes chemical compounds for therapeutic use. The company's approach aims to reprogram RNA processing to control gene expression, thereby correcting, enhancing, or eliminating problematic gene messages. This enables healthcare providers to tackle the underlying causes of diseases, offering novel solutions to previously undruggable conditions.

Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.

Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2017. The company focuses on developing human genetics-based therapeutics aimed at addressing ineffective red blood cell production in hematologic diseases. Its innovative pipeline includes therapies such as bitopertin for treating erythropoietic porphyrias and Diamond-Blackfan anemia. Disc Medicine targets the hepcidin metabolism axis and aims to modify fundamental biological pathways related to red blood cell formation and function, including heme biosynthesis and iron homeostasis. Through its portfolio of clinical and preclinical product candidates, the company strives to transform the lives of patients suffering from severe hematologic disorders.

Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies that target RNA processing to address various diseases. Established in 2018 and based in Cambridge, Massachusetts, the company employs its proprietary biology platform to identify and prioritize therapeutic targets within RNA processing. Through its REMseq platform, Remix Therapeutics validates potential drug targets and optimizes chemical compounds for therapeutic use. The company's approach aims to reprogram RNA processing to control gene expression, thereby correcting, enhancing, or eliminating problematic gene messages. This enables healthcare providers to tackle the underlying causes of diseases, offering novel solutions to previously undruggable conditions.

Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells to address various diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020 and based in Cambridge, Massachusetts, the company aims to overcome significant challenges associated with traditional cell and gene therapies, such as the limitations of dosing, unpredictable reactions in patients, and the necessity of pre-treatment chemotherapy. By leveraging precision genome editing, Be Biopharma creates durable and effective cell therapies that can be administered without toxic conditioning, thereby improving treatment options for conditions like Hemophilia B and enhancing overall patient outcomes.

HotSpot Therapeutics is a biotech startup established in 2017 and based in Boston, Massachusetts. The company specializes in developing allosteric therapies that target regulatory sites on proteins. Its innovative therapeutic platform is designed to identify hotspots and locate pathway treatments for a range of conditions, including cancer, metabolic disorders, and rare diseases. By leveraging a comprehensive database of hotspot structures and employing data science, HotSpot Therapeutics aims to enhance drug discovery and provide effective treatment options for patients with various health issues.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, founded in 2017. The company focuses on developing human genetics-based therapeutics aimed at addressing ineffective red blood cell production in hematologic diseases. Its innovative pipeline includes therapies such as bitopertin for treating erythropoietic porphyrias and Diamond-Blackfan anemia. Disc Medicine targets the hepcidin metabolism axis and aims to modify fundamental biological pathways related to red blood cell formation and function, including heme biosynthesis and iron homeostasis. Through its portfolio of clinical and preclinical product candidates, the company strives to transform the lives of patients suffering from severe hematologic disorders.

Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

Ikena Oncology is a biotechnology company based in Boston, Massachusetts, focused on developing innovative therapies for cancer treatment. The company specializes in biomarker-driven and precision therapies that target specific mechanisms involved in cancer growth, spread, and resistance. Its product pipeline includes several candidates such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-930, an oral small-molecule inhibitor of the TEAD transcription factor in the Hippo signaling pathway. Additionally, Ikena is exploring a kynurenine-degrading enzyme with IK-412 and other discovery-stage programs targeting various oncogenic pathways. Established in 2016, Ikena Oncology aims to address unmet medical needs through a combination of chemistry, translational science, and patient-centered drug development.

Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies that target RNA processing to address various diseases. Established in 2018 and based in Cambridge, Massachusetts, the company employs its proprietary biology platform to identify and prioritize therapeutic targets within RNA processing. Through its REMseq platform, Remix Therapeutics validates potential drug targets and optimizes chemical compounds for therapeutic use. The company's approach aims to reprogram RNA processing to control gene expression, thereby correcting, enhancing, or eliminating problematic gene messages. This enables healthcare providers to tackle the underlying causes of diseases, offering novel solutions to previously undruggable conditions.

Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.

Scorpion Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing next-generation precision oncology technologies for cancer treatment. Founded in 2020, the company specializes in creating targeted small-molecule drugs that interact with validated cancer targets. Its research encompasses therapies aimed at known oncogenes, previously undruggable cancer targets, and novel targets. By integrating technologies across target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics aims to advance a comprehensive pipeline of optimized compounds. The company's goal is to expand the reach of precision medicine, enabling healthcare professionals to offer innovative treatments to a broader range of cancer patients.

Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells to address various diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020 and based in Cambridge, Massachusetts, the company aims to overcome significant challenges associated with traditional cell and gene therapies, such as the limitations of dosing, unpredictable reactions in patients, and the necessity of pre-treatment chemotherapy. By leveraging precision genome editing, Be Biopharma creates durable and effective cell therapies that can be administered without toxic conditioning, thereby improving treatment options for conditions like Hemophilia B and enhancing overall patient outcomes.

Korro Bio Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing nucleic acid-based therapeutics aimed at editing RNA to treat rare and prevalent diseases. Founded in 2018, the company has created a proprietary platform that allows for efficient and selective RNA editing, leveraging natural processes found in multicellular organisms. This innovative approach enables precise modifications to messenger RNA, allowing for targeted changes in protein structure and function across various tissues. By focusing on RNA instead of DNA, Korro Bio aims to enhance the precision and adaptability of genetic medicines, expanding their potential applications in treating a range of medical conditions.

Dyne Therapeutics is a biotechnology company based in Waltham, Massachusetts, dedicated to developing targeted therapies for genetically driven muscle diseases. Founded in 2017, the company focuses on advancing treatments for conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, among others. Utilizing its innovative FORCE platform, Dyne Therapeutics aims to deliver disease-modifying therapies with enhanced precision to skeletal, cardiac, and smooth muscle tissues. The company's lead product candidates, DYNE-101 and DYNE-251, are currently undergoing phase 1/2 clinical trials, reflecting its commitment to addressing the unmet medical needs of patients with serious muscle disorders.

Aerovate Therapeutics is a clinical-stage biotechnology company based in Boston, Massachusetts, dedicated to developing innovative treatments for patients with rare cardiopulmonary diseases. The company's primary focus is on AV-101, a proprietary inhaled dry powder formulation of the drug imatinib, designed specifically for the treatment of pulmonary arterial hypertension (PAH). This formulation enables targeted delivery of the medication directly to affected lung tissues, thereby minimizing systemic side effects commonly associated with traditional treatments. Established in 2018, Aerovate aims to provide meaningful improvements in the lives of those suffering from these serious conditions.

Q32 Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for severe autoimmune and inflammatory diseases. Established in 2017, the company aims to address immune system dysregulation, providing treatment options for conditions that currently have limited or inadequate therapies. Q32 Bio's pipeline includes ADX-914, a human anti-IL-7R antibody designed to re-regulate adaptive immune function, and ADX-097, which demonstrates effective distribution to affected tissues and robust efficacy. With a team of experienced scientists and industry professionals, Q32 Bio is dedicated to restoring healthy immune balance through novel biologic therapies that target critical pathways in both the innate and adaptive immune systems.

HotSpot Therapeutics is a biotech startup established in 2017 and based in Boston, Massachusetts. The company specializes in developing allosteric therapies that target regulatory sites on proteins. Its innovative therapeutic platform is designed to identify hotspots and locate pathway treatments for a range of conditions, including cancer, metabolic disorders, and rare diseases. By leveraging a comprehensive database of hotspot structures and employing data science, HotSpot Therapeutics aims to enhance drug discovery and provide effective treatment options for patients with various health issues.

Cadent Therapeutics is a precision neuroscience company based in Cambridge, Massachusetts, founded in 2010. The company specializes in developing innovative allosteric modulators of ion channels, particularly targeting the NMDA receptor, to address a range of neurological and psychiatric disorders. Its research includes subunit-selective modulators aimed at treating conditions such as depression, schizophrenia, Rett syndrome, and other autism spectrum disorders. By focusing on drug design and optimization, patient selection, and quantitative endpoints, Cadent Therapeutics seeks to create first-in-class therapeutics that can restore cognitive and motor function in patients suffering from serious neurological diseases.

Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

Quench Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapies for inflammatory diseases through the exploration of gasdermin biology and innate immunity. The company’s lead compounds specifically target and inhibit Gasdermin D, a protein involved in the processes of pyroptosis and NETosis, which play a crucial role in the release of inflammatory cytokines, alarmins, DNA, and neutrophil extracellular traps (NETs). By addressing these pathways, Quench Bio aims to provide relief for patients suffering from severe inflammatory conditions. Originally founded as Project Pyro, the company changed its name to Quench Bio in June 2018.

Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies for both rare and prevalent diseases. Founded in 2016 and originally named Torus Therapeutics, the company focuses on treating conditions primarily affecting the liver and retina, as well as diseases of skeletal muscle, the central nervous system, and oncology. Generation Bio employs a proprietary non-viral platform that includes a high-capacity DNA construct known as closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP). This platform aims to deliver genetic payloads effectively across various tissues and allows for redosable treatments tailored to individual patient needs. Through its advanced manufacturing processes, Generation Bio seeks to expand access to gene therapies and provide durable solutions for patients with both rare and common diseases.

Triplet Therapeutics, Inc. is focused on developing innovative therapies for repeat expansion disorders, which include conditions such as Huntington’s disease, myotonic dystrophy, and spinocerebellar ataxias. Founded in 2018 and based in Cambridge, Massachusetts, the company aims to address these disorders at their source by utilizing a unique approach that involves targeting the DNA Damage Response pathway through a single oligonucleotide. This biotherapeutic technology is designed to provide a comprehensive treatment solution for multiple repeat expansion disorders, enabling healthcare professionals to better manage these complex conditions.

Arkuda Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. The company focuses on developing innovative medicines for patients suffering from neurological diseases, particularly targeting neurodegenerative conditions. Arkuda leverages insights into progranulin and lysosomal biology to create therapies aimed at addressing progranulin deficiency and lysosomal dysfunction, specifically in genetically-defined frontotemporal dementia related to mutations in the GRN gene. Its lead compounds are designed to improve cellular health in the brain, with the goal of delaying disease progression and the onset of symptoms.

Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies that target RNA processing to address various diseases. Established in 2018 and based in Cambridge, Massachusetts, the company employs its proprietary biology platform to identify and prioritize therapeutic targets within RNA processing. Through its REMseq platform, Remix Therapeutics validates potential drug targets and optimizes chemical compounds for therapeutic use. The company's approach aims to reprogram RNA processing to control gene expression, thereby correcting, enhancing, or eliminating problematic gene messages. This enables healthcare providers to tackle the underlying causes of diseases, offering novel solutions to previously undruggable conditions.

Triplet Therapeutics, Inc. is focused on developing innovative therapies for repeat expansion disorders, which include conditions such as Huntington’s disease, myotonic dystrophy, and spinocerebellar ataxias. Founded in 2018 and based in Cambridge, Massachusetts, the company aims to address these disorders at their source by utilizing a unique approach that involves targeting the DNA Damage Response pathway through a single oligonucleotide. This biotherapeutic technology is designed to provide a comprehensive treatment solution for multiple repeat expansion disorders, enabling healthcare professionals to better manage these complex conditions.

Cadent Therapeutics is a precision neuroscience company based in Cambridge, Massachusetts, founded in 2010. The company specializes in developing innovative allosteric modulators of ion channels, particularly targeting the NMDA receptor, to address a range of neurological and psychiatric disorders. Its research includes subunit-selective modulators aimed at treating conditions such as depression, schizophrenia, Rett syndrome, and other autism spectrum disorders. By focusing on drug design and optimization, patient selection, and quantitative endpoints, Cadent Therapeutics seeks to create first-in-class therapeutics that can restore cognitive and motor function in patients suffering from serious neurological diseases.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

HotSpot Therapeutics is a biotech startup established in 2017 and based in Boston, Massachusetts. The company specializes in developing allosteric therapies that target regulatory sites on proteins. Its innovative therapeutic platform is designed to identify hotspots and locate pathway treatments for a range of conditions, including cancer, metabolic disorders, and rare diseases. By leveraging a comprehensive database of hotspot structures and employing data science, HotSpot Therapeutics aims to enhance drug discovery and provide effective treatment options for patients with various health issues.

Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.

Generation Bio is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies for both rare and prevalent diseases. Founded in 2016 and originally named Torus Therapeutics, the company focuses on treating conditions primarily affecting the liver and retina, as well as diseases of skeletal muscle, the central nervous system, and oncology. Generation Bio employs a proprietary non-viral platform that includes a high-capacity DNA construct known as closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP). This platform aims to deliver genetic payloads effectively across various tissues and allows for redosable treatments tailored to individual patient needs. Through its advanced manufacturing processes, Generation Bio seeks to expand access to gene therapies and provide durable solutions for patients with both rare and common diseases.

Korro Bio Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing nucleic acid-based therapeutics aimed at editing RNA to treat rare and prevalent diseases. Founded in 2018, the company has created a proprietary platform that allows for efficient and selective RNA editing, leveraging natural processes found in multicellular organisms. This innovative approach enables precise modifications to messenger RNA, allowing for targeted changes in protein structure and function across various tissues. By focusing on RNA instead of DNA, Korro Bio aims to enhance the precision and adaptability of genetic medicines, expanding their potential applications in treating a range of medical conditions.

Quench Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapies for inflammatory diseases through the exploration of gasdermin biology and innate immunity. The company’s lead compounds specifically target and inhibit Gasdermin D, a protein involved in the processes of pyroptosis and NETosis, which play a crucial role in the release of inflammatory cytokines, alarmins, DNA, and neutrophil extracellular traps (NETs). By addressing these pathways, Quench Bio aims to provide relief for patients suffering from severe inflammatory conditions. Originally founded as Project Pyro, the company changed its name to Quench Bio in June 2018.

Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that specializes in the discovery and development of novel small molecule therapeutics aimed at selectively degrading disease-causing proteins. The company utilizes a proprietary platform for targeted protein degradation, leveraging the body’s natural protein recycling system. Kymera is developing several programs, including the IRAK4 program for immunology-inflammation diseases such as hidradenitis suppurativa and rheumatoid arthritis, the IRAKIMiD program to address MYD88-mutated diffuse large B cell lymphoma, and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. Founded in 2015, Kymera Therapeutics is pioneering new approaches to treat diseases that have previously been considered untreatable, focusing on previously inaccessible therapeutic targets.

Gemini Therapeutics, Inc. is a precision medicine company based in Cambridge, Massachusetts, established in 2015. The company is dedicated to developing innovative therapies for patients with dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini Therapeutics focuses on genetically defined conditions, ensuring that their therapeutic candidates are tailored to the specific molecular abnormalities found in patients with significant clinical needs. Their extensive pipeline includes a range of modalities such as monoclonal antibodies, recombinant proteins, and gene therapies. Supported by prominent life science investors and global academic collaborations, Gemini Therapeutics aims to create potentially first-in-class therapeutics to address unmet medical needs in the field of ophthalmology.

Disarm Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for patients suffering from neurological diseases. Founded in 2016 and headquartered in Cambridge, Massachusetts, the company aims to create disease-modifying drugs that prevent axonal degeneration, which is a key factor in various neurological disorders. Disarm's portfolio addresses conditions such as multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies, providing potential treatments for acute diseases affecting the central, ocular, and peripheral nervous systems. As of late 2020, Disarm Therapeutics operates as a subsidiary of Eli Lilly and Company.

Replimune Group is a biotechnology company focused on developing oncolytic immune-gene therapies for cancer treatment. Utilizing its proprietary Immulytic platform, Replimune aims to create product candidates that activate the immune system against tumors. The company's lead candidate, RP1, is a modified herpes simplex virus currently undergoing Phase I/II clinical trials for various solid tumors and Phase II trials specifically for cutaneous squamous cell carcinoma. Additionally, Replimune is developing RP2, which targets CTLA-4 to enhance immune response, and RP3, designed to express immune-activating proteins that stimulate T cells. Founded in 2015 and based in Woburn, Massachusetts, Replimune seeks to advance its therapies through clinical trials and explore combinations with other immuno-oncology treatments to enhance efficacy.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

Magenta Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies to enhance stem cell transplantation for patients with blood cancers, genetic diseases, and autoimmune disorders. The company aims to improve the safety and efficacy of stem cell transplants, which are currently high-risk procedures often considered only as a last resort. Its pipeline includes several key product candidates, such as targeted antibody-drug conjugates for transplant conditioning, a novel stem cell mobilization agent, and allogeneic stem cell therapies. Magenta is also exploring collaborations to assess the effectiveness of its therapies in combination with existing treatments, such as gene therapies for sickle cell disease. Founded in 2015 and headquartered in Cambridge, Massachusetts, Magenta Therapeutics seeks to expand the curative potential of stem cell therapies to a broader patient population by addressing the toxicity and long-term side effects associated with current transplant methods.

SimpleReach, Inc. provides a platform that tracks social interaction with published content to deliver insights and performance metrics related to social behavior. By integrating data from various channels and websites, the company offers a comprehensive view of content effectiveness, helping clients enhance their return on content investments. Utilizing advanced machine learning and artificial intelligence, SimpleReach assists marketers in refining future campaigns and enables publishers to create dashboards for monitoring and reporting on campaign performance. The company serves a range of clients, including notable brands like Intel, Chase, and Home Depot, who rely on its platform to gain actionable insights and improve content impact. Founded in 2010 and based in New York, SimpleReach operates as a subsidiary of Nativo, Inc. since March 2019.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. The company’s leading product candidate, tebipenem pivoxil hydrobromide, is an oral antibiotic designed to treat MDR Gram-negative infections in adults. Additionally, Spero is advancing SPR206, an intravenous agent targeting MDR Gram-negative infections, and SPR720, an oral antibiotic aimed at treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics collaborates with various organizations, including Meiji Seika Pharma for tebipenem HBr, Everest Medicines for SPR206 in Asia, and the Bill & Melinda Gates Medical Research Institute for SPR720. Founded in 2013, Spero leverages a strong team in chemistry and microbiology to address significant unmet medical needs in infectious disease treatment.

Translate Bio, Inc. is a clinical-stage biotechnology company focused on developing messenger RNA (mRNA) therapeutics aimed at addressing diseases linked to protein or gene dysfunction. Founded in 2011 and based in Lexington, Massachusetts, the company is advancing its lead candidates, MRT5005 and MRT5201. MRT5005 is currently undergoing Phase I/II clinical trials for the treatment of cystic fibrosis, while MRT5201 is being developed to treat ornithine transcarbamylase deficiency. Translate Bio aims to create innovative medicines that have the potential to significantly impact the treatment landscape for rare diseases.

Magenta Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies to enhance stem cell transplantation for patients with blood cancers, genetic diseases, and autoimmune disorders. The company aims to improve the safety and efficacy of stem cell transplants, which are currently high-risk procedures often considered only as a last resort. Its pipeline includes several key product candidates, such as targeted antibody-drug conjugates for transplant conditioning, a novel stem cell mobilization agent, and allogeneic stem cell therapies. Magenta is also exploring collaborations to assess the effectiveness of its therapies in combination with existing treatments, such as gene therapies for sickle cell disease. Founded in 2015 and headquartered in Cambridge, Massachusetts, Magenta Therapeutics seeks to expand the curative potential of stem cell therapies to a broader patient population by addressing the toxicity and long-term side effects associated with current transplant methods.

Gemini Therapeutics, Inc. is a precision medicine company based in Cambridge, Massachusetts, established in 2015. The company is dedicated to developing innovative therapies for patients with dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini Therapeutics focuses on genetically defined conditions, ensuring that their therapeutic candidates are tailored to the specific molecular abnormalities found in patients with significant clinical needs. Their extensive pipeline includes a range of modalities such as monoclonal antibodies, recombinant proteins, and gene therapies. Supported by prominent life science investors and global academic collaborations, Gemini Therapeutics aims to create potentially first-in-class therapeutics to address unmet medical needs in the field of ophthalmology.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. The company’s leading product candidate, tebipenem pivoxil hydrobromide, is an oral antibiotic designed to treat MDR Gram-negative infections in adults. Additionally, Spero is advancing SPR206, an intravenous agent targeting MDR Gram-negative infections, and SPR720, an oral antibiotic aimed at treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics collaborates with various organizations, including Meiji Seika Pharma for tebipenem HBr, Everest Medicines for SPR206 in Asia, and the Bill & Melinda Gates Medical Research Institute for SPR720. Founded in 2013, Spero leverages a strong team in chemistry and microbiology to address significant unmet medical needs in infectious disease treatment.

Navitor Pharmaceuticals is a developer of novel medicines designed to target specific nutrient-sensing proteins that selectively regulate mTORC1 activity to treat diseases. The company's medicines selectively modulate the activity of mTORC1, a master regulator of cell growth and metabolism, and unlock the therapeutic potential of the mTOR pathway by targeting the amino acid and other nutrient sensors that selectively regulate the activity of mTORC1, enabling healthcare practitioners to address a wide range of metabolic, neurodegenerative, autoimmune and musculoskeletal diseases. It was founded in 2009 and headquartered in Cambridge, Massachusetts.

Replimune Group is a biotechnology company focused on developing oncolytic immune-gene therapies for cancer treatment. Utilizing its proprietary Immulytic platform, Replimune aims to create product candidates that activate the immune system against tumors. The company's lead candidate, RP1, is a modified herpes simplex virus currently undergoing Phase I/II clinical trials for various solid tumors and Phase II trials specifically for cutaneous squamous cell carcinoma. Additionally, Replimune is developing RP2, which targets CTLA-4 to enhance immune response, and RP3, designed to express immune-activating proteins that stimulate T cells. Founded in 2015 and based in Woburn, Massachusetts, Replimune seeks to advance its therapies through clinical trials and explore combinations with other immuno-oncology treatments to enhance efficacy.

Intellia Therapeutics is a genome editing company headquartered in Cambridge, Massachusetts, that specializes in developing innovative therapeutics using the CRISPR/Cas9 technology. The company focuses on in vivo programs targeting liver diseases such as transthyretin amyloidosis and hereditary angioedema, as well as conditions like primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Additionally, Intellia's ex vivo pipeline includes engineered cell therapies aimed at treating various oncological and autoimmune diseases. The company has entered into collaborations with notable organizations, including Novartis and Regeneron Pharmaceuticals, to advance its research and development efforts. Founded in 2014, Intellia Therapeutics is committed to addressing severe and life-threatening diseases through its comprehensive intellectual property platform and a broad range of clinical development programs.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. The company’s leading product candidate, tebipenem pivoxil hydrobromide, is an oral antibiotic designed to treat MDR Gram-negative infections in adults. Additionally, Spero is advancing SPR206, an intravenous agent targeting MDR Gram-negative infections, and SPR720, an oral antibiotic aimed at treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics collaborates with various organizations, including Meiji Seika Pharma for tebipenem HBr, Everest Medicines for SPR206 in Asia, and the Bill & Melinda Gates Medical Research Institute for SPR720. Founded in 2013, Spero leverages a strong team in chemistry and microbiology to address significant unmet medical needs in infectious disease treatment.

Nimbus Therapeutics, based in Cambridge, Massachusetts, is a biotechnology company focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. The company utilizes advanced computational technologies to create selective and potent small-molecule therapeutics. Among its notable projects is the Nimbus Apollo program, which features the lead candidate NDI-010976, an allosteric inhibitor targeting Acetyl-CoA Carboxylase (ACC). This compound is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and has potential applications in hepatocellular carcinoma (HCC) and other diseases. NDI-010976 received Fast Track designation from the U.S. Food and Drug Administration in 2016, highlighting its significance in the clinical development pipeline. Nimbus Therapeutics has formed strategic partnerships to enhance its research and development capabilities, reinforcing its commitment to advancing treatment options for complex health challenges.

Surface Oncology, Inc. is a clinical-stage immuno-oncology company focused on developing innovative cancer therapies. The company is advancing a pipeline of monoclonal antibodies, including SRF231, which inhibits CD47; NZV930, targeting CD73; SRF617, aimed at CD39; SRF388, which targets interleukin 27; and SRF813, focused on CD112R. Additionally, Surface is exploring earlier-stage programs that address critical elements of the tumor microenvironment, such as regulatory T cells and natural killer cells. The company has established collaborations with notable partners, including Novartis Institutes for Biomedical Research for cancer therapy development and Merck Sharp & Dohme Corp. to assess the safety and efficacy of combining SRF617 with KEYTRUDA, an anti-PD-1 therapy. Founded in 2014 and headquartered in Cambridge, Massachusetts, Surface Oncology aims to create conditions that enhance anti-tumor immune responses through its targeted approaches in cancer immunotherapy.

Appcues, Inc. operates a Software-as-a-Service platform that allows businesses to create personalized user onboarding experiences without the need for coding. Founded in 2013 and based in Boston, Massachusetts, Appcues provides tools that enable non-technical teams to design, publish, and manage onboarding flows, thereby enhancing product adoption and retention rates. The platform allows users to track and analyze product usage, capture user feedback, and implement in-app tours, announcements, and surveys quickly and efficiently. Appcues is utilized by numerous product-led companies globally, helping them improve their user experience and gain valuable insights into user behavior.

Padlock Therapeutics is a biotechnology company focused on developing innovative medicines that target protein-arginine deiminases (PADs), enzymes implicated in the generation of autoantigens and the inflammatory processes associated with autoimmune diseases. Founded by scientists from The Scripps Research Institute and members of the Atlas Venture Life Sciences Team, Padlock aims to explore the biological and therapeutic potential of protein deimination by PADs. The company operates as a seed-stage entity based in Cambridge, Massachusetts, and is backed by notable investors, including Atlas Venture, Johnson & Johnson, and MS Ventures.

Intellia Therapeutics is a genome editing company headquartered in Cambridge, Massachusetts, that specializes in developing innovative therapeutics using the CRISPR/Cas9 technology. The company focuses on in vivo programs targeting liver diseases such as transthyretin amyloidosis and hereditary angioedema, as well as conditions like primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Additionally, Intellia's ex vivo pipeline includes engineered cell therapies aimed at treating various oncological and autoimmune diseases. The company has entered into collaborations with notable organizations, including Novartis and Regeneron Pharmaceuticals, to advance its research and development efforts. Founded in 2014, Intellia Therapeutics is committed to addressing severe and life-threatening diseases through its comprehensive intellectual property platform and a broad range of clinical development programs.

InsightSquared, Inc. specializes in developing sales performance analytics solutions tailored for software as a service (SaaS) businesses. The company provides a comprehensive Revenue Intelligence Platform that integrates multiple tools, including Tiles for sales analytics and Slate for report building, which analyzes data from various sources to generate actionable insights. InsightSquared's offerings encompass sales development, demand generation, marketing analytics, and staffing analytics, enabling organizations to track key performance indicators, improve conversion rates, and enhance forecast accuracy. Established in 2010 and based in Boston, Massachusetts, with an additional office in Austin, Texas, InsightSquared aims to empower businesses to make informed decisions that promote predictable growth and strengthen their sales pipelines.

Quartet Medicine, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative treatments for chronic pain and inflammation. Founded in 2013 by scientists from Boston Children’s Hospital and École Polytechnique Fédérale de Lausanne, Quartet aims to restore tetrahydrobiopterin (BH4) homeostasis in neuronal and inflammatory cells. Research indicates that increased levels of BH4 are essential for regulating peripheral nerve function and immune responses. By leveraging these insights, Quartet is working on novel non-opioid medications that target this biochemical pathway, providing an alternative approach to managing pain and inflammation. The company collaborates with various research partners in Europe and Asia to advance its therapeutic offerings.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

CardFlight, Inc. specializes in mobile point of sale (POS) technology solutions that enable small businesses to accept swiped payments through various mobile applications. Its flagship product, SwipeSimple, is used by over 50,000 small businesses across the United States and is recommended by several leading merchant acquirers for its ease of use. The company provides a comprehensive suite of tools, including a mobile card reader that connects via the headphone jack of mobile devices, and a software development kit (SDK) for iOS and Android, which allows developers to integrate payment processing into their applications. CardFlight’s solutions cater to various industries, including retail, food and beverage, and professional services, supporting electronic transaction processing for in-person, online, and on-the-go payments. Established in 2011 and based in New York, CardFlight is recognized for its technological innovation and commitment to simplifying payment acceptance for business owners.

Kinvey, Inc. offers a mobile backend as a service (mBaaS) platform designed to simplify the development of cloud backends for mobile, tablet, and web applications. Established in 2008 and based in Boston, Massachusetts, Kinvey enables developers to focus exclusively on application development without the burden of managing server infrastructure or integrating various cloud services. The platform provides automated API generation, allowing developers to seamlessly connect their applications to backend services. Kinvey's solutions cater to a diverse range of industries, including healthcare, finance, utilities, and media, facilitating features such as data storage, user management, push notifications, and analytics. As of June 2017, Kinvey operates as a subsidiary of Progress Software Corporation.

Veracode is an independent provider of cloud-based application security and intelligence services, founded in 2006 and headquartered in Burlington, Massachusetts. The company offers a platform designed to identify and remediate security-related vulnerabilities throughout the software development lifecycle. By integrating security seamlessly into the development process, Veracode enables security teams, software developers, and enterprises to test and monitor the security of both internally developed and third-party applications. This comprehensive solution enhances the security of web, mobile, and outsourced software applications, ensuring that organizations can effectively address potential defects from the inception of their software projects.

Q4 Inc. is a cloud-based provider of investor relations and capital market solutions, serving clients in Canada and internationally. The company offers a comprehensive suite of services, including Q4 Desktop, which equips clients with essential tools and insights for effective investor communication and engagement. Q4 specializes in designing and developing investor relations websites, delivering online reports, and offering a range of audio/video webcasting and conferencing services for organizations of all sizes. Their platform facilitates detailed analytics on trading behaviors, institutional stockholder activity, and market trends, providing actionable intelligence for investor relations officers and C-suite executives. Additionally, Q4 enhances clients' online presence and engagement capabilities through innovative storytelling approaches to corporate reporting. With a focus on customer support and a commitment to improving investor relations effectiveness, Q4 serves over 2,200 major brands and operates from offices in Toronto, New York, Chicago, and Copenhagen.

Surface Oncology, Inc. is a clinical-stage immuno-oncology company focused on developing innovative cancer therapies. The company is advancing a pipeline of monoclonal antibodies, including SRF231, which inhibits CD47; NZV930, targeting CD73; SRF617, aimed at CD39; SRF388, which targets interleukin 27; and SRF813, focused on CD112R. Additionally, Surface is exploring earlier-stage programs that address critical elements of the tumor microenvironment, such as regulatory T cells and natural killer cells. The company has established collaborations with notable partners, including Novartis Institutes for Biomedical Research for cancer therapy development and Merck Sharp & Dohme Corp. to assess the safety and efficacy of combining SRF617 with KEYTRUDA, an anti-PD-1 therapy. Founded in 2014 and headquartered in Cambridge, Massachusetts, Surface Oncology aims to create conditions that enhance anti-tumor immune responses through its targeted approaches in cancer immunotherapy.

DraftKings Inc. is a digital sports entertainment and gaming company based in Boston, Massachusetts. It offers users opportunities for daily sports contests, sports betting, and iGaming across the United States and Canada. Since its inception in 2012, DraftKings has grown from an innovator in daily fantasy sports to a major player in online sports wagering and casino gaming, especially following a Supreme Court ruling in 2018 that allowed states to legalize such activities. The company operates in 27 states for online or retail sports betting and in seven states for iGaming, reaching approximately 40% of Canada's population. DraftKings also develops software for sports betting and casino gaming, distributing its products through websites, app downloads, and direct-to-consumer platforms. Additionally, it features a marketplace for non-fungible tokens and licenses online gaming products.

Fancred Inc. is a social platform designed for sports enthusiasts, allowing them to enhance their sports credibility and connect with fellow fans. Founded in August 2012 by Hossein Kash Razzaghi, Jeremy Merle, Craig Johnson, and Michael Pan, the company is based in Brookline, Massachusetts. Fancred enables users to share opinions, photos, videos, and articles related to their favorite teams, fostering a community where sports fans can interact and engage with relevant content. The platform also offers a mobile application that allows users to follow teams and build their reputation based on their passion and knowledge within the sports community.

DataRobot, Inc. develops an automated machine learning platform that empowers enterprises to create predictive models efficiently. Its offerings include DataRobot Cloud, a predictive analytics solution available both in the cloud and on-premises, and DataRobot MLOps, which facilitates the deployment, monitoring, and management of machine learning models across organizations. The company also provides DataRobot Enterprise, featuring flexible deployment options, governance, and training services, along with packages designed to accelerate artificial intelligence projects. DataRobot serves a diverse range of industries, including banking, healthcare, manufacturing, and marketing, catering to business analysts, data scientists, and IT professionals. Founded in 2012 and headquartered in Boston, Massachusetts, DataRobot has expanded its operations globally, with offices in major cities such as London, Paris, and Tokyo, and maintains strategic partnerships to enhance its offerings.

Drop, Inc. is a location-based messaging platform designed for iPhone users, enabling them to send and receive messages linked to specific geographical locations. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company offers an app that notifies users when they are near friends or photos from accounts they follow. Users can leave "drops," which are photos associated with particular places, allowing followers to discover these images in real-world locations. The app also integrates with Instagram, automatically converting posts into drops and providing alerts when friends visit nearby venues. This functionality allows users to stay connected with friends at events or popular spots, enhancing social interactions through location-aware notifications. The Drop community has expanded to over 85 countries and more than 150 college campuses across the United States, fostering a vibrant network of users engaged in location-based sharing.

Ready4, Inc. is a Boston-based company that develops a mobile study application aimed at helping students prepare for standardized exams, including the GMAT, GRE, SAT, ACT, PSAT, and MCAT. Founded in 2012, Ready4 has gained popularity with over 1 million downloads across more than 195 countries. The platform not only offers test preparation resources but also includes tools for school research, application planning, and scholarship opportunities. Additionally, Ready4 features a tutor marketplace that connects students with educators, enhancing their learning experience. Universities can collaborate with Ready4 to engage with prospective students globally, facilitating a more tailored admissions process. The company operates as a subsidiary of TAL Education Group, continuing its mission to connect students with educational opportunities.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

Fortified Bicycle, Inc. is a manufacturer based in Cambridge, Massachusetts, that specializes in LED bicycle headlights designed specifically for urban cyclists. Founded in 2012, the company provides a range of anti-theft bike headlights and accessories aimed at enhancing the security and convenience of cycling in urban environments. Its product offerings include rechargeable lights, seat security solutions, and batteries, which are available through various retailers and bike dealers. The company was originally established as Gotham Bicycle Defense Industries, LLC, and has evolved to focus on providing theft-resistant commuting solutions for cyclists.

SimpleReach, Inc. provides a platform that tracks social interaction with published content to deliver insights and performance metrics related to social behavior. By integrating data from various channels and websites, the company offers a comprehensive view of content effectiveness, helping clients enhance their return on content investments. Utilizing advanced machine learning and artificial intelligence, SimpleReach assists marketers in refining future campaigns and enables publishers to create dashboards for monitoring and reporting on campaign performance. The company serves a range of clients, including notable brands like Intel, Chase, and Home Depot, who rely on its platform to gain actionable insights and improve content impact. Founded in 2010 and based in New York, SimpleReach operates as a subsidiary of Nativo, Inc. since March 2019.

Navitor Pharmaceuticals is a developer of novel medicines designed to target specific nutrient-sensing proteins that selectively regulate mTORC1 activity to treat diseases. The company's medicines selectively modulate the activity of mTORC1, a master regulator of cell growth and metabolism, and unlock the therapeutic potential of the mTOR pathway by targeting the amino acid and other nutrient sensors that selectively regulate the activity of mTORC1, enabling healthcare practitioners to address a wide range of metabolic, neurodegenerative, autoimmune and musculoskeletal diseases. It was founded in 2009 and headquartered in Cambridge, Massachusetts.

WHOOP is the performance optimization system that tracks recovery, training, and sleeping hours thus helping elite athletes and teams win. The company provides athletes, coaches, and trainers with a continuous understanding of strain and recovery to balance training, reduce injuries, and predict performance. It creates a product that makes individuals and teams perform at a higher level through a deeper understanding of their bodies and daily lives. The WHOOP Strap 3.0 collects physiological data 24/7 to provide an accurate and granular understanding of the body. Aurelian Nicolae, John Capodilupo, and Will Ahmed established WHOOP in 2012 and in Boston, Massachusetts.

Allclasses, Inc. is an online search engine that enables users to find and explore a wide variety of classes and class providers, both locally and online. Founded in 2013 and headquartered in Boston, Massachusetts, the platform serves as a comprehensive resource connecting individuals to millions of educational and experiential opportunities, including courses in academics, professional skills, fitness, art, and more. Allclasses aims to simplify the search process by providing an objective tool that evaluates classes based on accessibility, cost, and quality, thus promoting lifelong learning. As a subsidiary of Noodle Education, Inc., Allclasses is dedicated to helping individuals design personal and professional growth through diverse learning experiences.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. The company’s leading product candidate, tebipenem pivoxil hydrobromide, is an oral antibiotic designed to treat MDR Gram-negative infections in adults. Additionally, Spero is advancing SPR206, an intravenous agent targeting MDR Gram-negative infections, and SPR720, an oral antibiotic aimed at treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics collaborates with various organizations, including Meiji Seika Pharma for tebipenem HBr, Everest Medicines for SPR206 in Asia, and the Bill & Melinda Gates Medical Research Institute for SPR720. Founded in 2013, Spero leverages a strong team in chemistry and microbiology to address significant unmet medical needs in infectious disease treatment.

Ataxion is a discovery-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapies for rare and underserved neurologic diseases. Founded in April 2013 by Dr. Josh Resnick and David Grayzel, MD, through the Atlas Venture seed program, Ataxion specializes in small-molecule therapeutics that target hereditary ataxia and other degenerative neurological disorders such as multiple sclerosis and Huntington's disease. By leveraging ion-channel modulators, the company aims to provide effective treatments for patients suffering from these debilitating conditions.

Carbon Black, Inc. is a cybersecurity company that offers advanced security solutions both in the United States and globally. Established in 2002 and headquartered in Waltham, Massachusetts, the company provides a range of products aimed at predicting, preventing, detecting, responding to, and remediating cyber threats. Its flagship offering, the Cb Predictive Security Cloud, is a big data and analytics platform that enables comprehensive endpoint data collection and analysis. Carbon Black's product suite includes CB Defense for antivirus and endpoint detection, CB ThreatHunter for threat hunting, and CB LiveOps for real-time security operations. Additionally, it provides managed services through CB ThreatSight and application control via CB Protection. The company serves a diverse clientele, including security-focused enterprises, government agencies, and small to mid-sized organizations, and has been recognized for its innovative approach to endpoint security. In January 2016, Carbon Black rebranded from its original name, Bit9, Inc., and it currently operates as a subsidiary of VMware.

dataxu, inc. is a marketing analytics software company that provides solutions for brand marketers and agencies globally. Founded in 2007 and headquartered in Boston, Massachusetts, the company offers a range of products including TouchPoint, a demand side platform for multi-channel marketing; OneView, which helps marketers build a comprehensive understanding of consumer behavior; and the Marketing Intelligence Center, a dashboard that consolidates data and performance metrics. Other offerings include ClearSight, an analytics platform for customer insights, and TotalTV, which facilitates audience-based targeting across various TV formats. dataxu also produces insights through white papers and reports, and provides training and managed services for its platform users. The company serves diverse industries such as automotive, financial services, and consumer packaged goods. As a subsidiary of Roku, Inc., dataxu continues to focus on enhancing marketing effectiveness through data-driven strategies.

Integral Ad Science operates as a media valuation platform that helps digital buyers and sellers evaluate the quality and effectiveness of their advertising opportunities across various channels and devices. The company provides a range of solutions designed to enhance the digital advertising ecosystem, including customizable verification tools that help advertisers block unwanted impressions and assess return on investment. Its offerings include dynamic data solutions for programmatic buying and API integration tools for inventory quality insights. Integral Ad Science also focuses on ensuring brand safety, viewability, and fraud prevention in digital advertising placements. By delivering independent measurement and verification across all media formats, the company aims to establish trust and transparency in digital media quality for brands, publishers, and advertising platforms worldwide. Founded in 2008 and headquartered in New York City, Integral Ad Science has expanded its presence globally with offices in multiple countries.

SecurityScorecard, Inc. is a cybersecurity firm that specializes in providing a comprehensive rating and continuous monitoring platform to assess the cybersecurity strength of businesses and their third-party vendors. Established in 2013 by experts in security and risk, the company offers a range of solutions, including ThreatMarket, a cloud-based vulnerability search engine that identifies and correlates security-risk indicators across multiple categories such as application security and network vulnerabilities. Its services support vendor risk management, board reporting, and cyber insurance underwriting for over 1,000 organizations, including Fortune 1000 companies globally. SecurityScorecard's innovative approach includes interactive tools like Score Planner for remediation planning, Scorecard Event Log for transparent score tracking, and Atlas for managing cybersecurity questionnaires and controls at scale. By providing real-time risk ratings that align with vendor cybersecurity assessments, SecurityScorecard enhances organizational resilience and improves communication of cybersecurity risks to stakeholders. The company is headquartered in New York, New York.

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. The company’s leading product candidate, tebipenem pivoxil hydrobromide, is an oral antibiotic designed to treat MDR Gram-negative infections in adults. Additionally, Spero is advancing SPR206, an intravenous agent targeting MDR Gram-negative infections, and SPR720, an oral antibiotic aimed at treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics collaborates with various organizations, including Meiji Seika Pharma for tebipenem HBr, Everest Medicines for SPR206 in Asia, and the Bill & Melinda Gates Medical Research Institute for SPR720. Founded in 2013, Spero leverages a strong team in chemistry and microbiology to address significant unmet medical needs in infectious disease treatment.

DraftKings Inc. is a digital sports entertainment and gaming company based in Boston, Massachusetts. It offers users opportunities for daily sports contests, sports betting, and iGaming across the United States and Canada. Since its inception in 2012, DraftKings has grown from an innovator in daily fantasy sports to a major player in online sports wagering and casino gaming, especially following a Supreme Court ruling in 2018 that allowed states to legalize such activities. The company operates in 27 states for online or retail sports betting and in seven states for iGaming, reaching approximately 40% of Canada's population. DraftKings also develops software for sports betting and casino gaming, distributing its products through websites, app downloads, and direct-to-consumer platforms. Additionally, it features a marketplace for non-fungible tokens and licenses online gaming products.

Fancred Inc. is a social platform designed for sports enthusiasts, allowing them to enhance their sports credibility and connect with fellow fans. Founded in August 2012 by Hossein Kash Razzaghi, Jeremy Merle, Craig Johnson, and Michael Pan, the company is based in Brookline, Massachusetts. Fancred enables users to share opinions, photos, videos, and articles related to their favorite teams, fostering a community where sports fans can interact and engage with relevant content. The platform also offers a mobile application that allows users to follow teams and build their reputation based on their passion and knowledge within the sports community.

CardFlight, Inc. specializes in mobile point of sale (POS) technology solutions that enable small businesses to accept swiped payments through various mobile applications. Its flagship product, SwipeSimple, is used by over 50,000 small businesses across the United States and is recommended by several leading merchant acquirers for its ease of use. The company provides a comprehensive suite of tools, including a mobile card reader that connects via the headphone jack of mobile devices, and a software development kit (SDK) for iOS and Android, which allows developers to integrate payment processing into their applications. CardFlight’s solutions cater to various industries, including retail, food and beverage, and professional services, supporting electronic transaction processing for in-person, online, and on-the-go payments. Established in 2011 and based in New York, CardFlight is recognized for its technological innovation and commitment to simplifying payment acceptance for business owners.

DataRobot, Inc. develops an automated machine learning platform that empowers enterprises to create predictive models efficiently. Its offerings include DataRobot Cloud, a predictive analytics solution available both in the cloud and on-premises, and DataRobot MLOps, which facilitates the deployment, monitoring, and management of machine learning models across organizations. The company also provides DataRobot Enterprise, featuring flexible deployment options, governance, and training services, along with packages designed to accelerate artificial intelligence projects. DataRobot serves a diverse range of industries, including banking, healthcare, manufacturing, and marketing, catering to business analysts, data scientists, and IT professionals. Founded in 2012 and headquartered in Boston, Massachusetts, DataRobot has expanded its operations globally, with offices in major cities such as London, Paris, and Tokyo, and maintains strategic partnerships to enhance its offerings.

WHOOP is the performance optimization system that tracks recovery, training, and sleeping hours thus helping elite athletes and teams win. The company provides athletes, coaches, and trainers with a continuous understanding of strain and recovery to balance training, reduce injuries, and predict performance. It creates a product that makes individuals and teams perform at a higher level through a deeper understanding of their bodies and daily lives. The WHOOP Strap 3.0 collects physiological data 24/7 to provide an accurate and granular understanding of the body. Aurelian Nicolae, John Capodilupo, and Will Ahmed established WHOOP in 2012 and in Boston, Massachusetts.

Privy, Inc. operates a web marketing platform aimed at helping small businesses, particularly in e-commerce, enhance their customer engagement and conversion rates. Founded in 2011 and based in Boston, Massachusetts, Privy offers a variety of tools that simplify the process of building email lists and improving on-site marketing. Its features include customizable pop-ups, banners, and exit intent options designed to convert website traffic into email subscribers. Additionally, Privy provides landing pages for tracking conversions across social and advertising networks, as well as an email collection application for acquiring addresses from in-store customers at events. The company focuses on empowering small e-commerce brands, local businesses, and content publishers by providing the necessary resources and support to grow their online presence and drive sales.

Cadent Therapeutics is a precision neuroscience company based in Cambridge, Massachusetts, founded in 2010. The company specializes in developing innovative allosteric modulators of ion channels, particularly targeting the NMDA receptor, to address a range of neurological and psychiatric disorders. Its research includes subunit-selective modulators aimed at treating conditions such as depression, schizophrenia, Rett syndrome, and other autism spectrum disorders. By focusing on drug design and optimization, patient selection, and quantitative endpoints, Cadent Therapeutics seeks to create first-in-class therapeutics that can restore cognitive and motor function in patients suffering from serious neurological diseases.

InsightSquared, Inc. specializes in developing sales performance analytics solutions tailored for software as a service (SaaS) businesses. The company provides a comprehensive Revenue Intelligence Platform that integrates multiple tools, including Tiles for sales analytics and Slate for report building, which analyzes data from various sources to generate actionable insights. InsightSquared's offerings encompass sales development, demand generation, marketing analytics, and staffing analytics, enabling organizations to track key performance indicators, improve conversion rates, and enhance forecast accuracy. Established in 2010 and based in Boston, Massachusetts, with an additional office in Austin, Texas, InsightSquared aims to empower businesses to make informed decisions that promote predictable growth and strengthen their sales pipelines.

DraftKings Inc. is a digital sports entertainment and gaming company based in Boston, Massachusetts. It offers users opportunities for daily sports contests, sports betting, and iGaming across the United States and Canada. Since its inception in 2012, DraftKings has grown from an innovator in daily fantasy sports to a major player in online sports wagering and casino gaming, especially following a Supreme Court ruling in 2018 that allowed states to legalize such activities. The company operates in 27 states for online or retail sports betting and in seven states for iGaming, reaching approximately 40% of Canada's population. DraftKings also develops software for sports betting and casino gaming, distributing its products through websites, app downloads, and direct-to-consumer platforms. Additionally, it features a marketplace for non-fungible tokens and licenses online gaming products.

Gizmox Ltd. specializes in providing an enterprise HTML5 platform aimed at transforming data-driven desktop applications into secure web and mobile applications. Founded in 2007 and based in Cambridge, Massachusetts, with an additional office in Kfar Saba, Israel, Gizmox offers products such as Visual WebGui, which enables Visual Studio developers to create enterprise-class HTML5 applications for various devices, and Gizmox Transposition, an assessment tool for converting existing client-server applications into web-optimized formats. The company serves a diverse clientele that includes Fortune 500 companies across sectors such as banking, insurance, and government. With a focus on mobility and BYOD, Gizmox equips development teams with the necessary tools to deliver scalable and secure business applications efficiently.

Timbre is a location-based live music discovery application based in Cambridge, Massachusetts. The app allows users to find live shows and concerts in their vicinity by displaying a calendar of upcoming performances based on their location or any specified area. Users can listen to music samples from the performing bands, purchase tickets, and share events with friends, all within a user-friendly interface. By facilitating easy access to live music events, Timbre aims to enhance the concert-going experience for music enthusiasts.

dataxu, inc. is a marketing analytics software company that provides solutions for brand marketers and agencies globally. Founded in 2007 and headquartered in Boston, Massachusetts, the company offers a range of products including TouchPoint, a demand side platform for multi-channel marketing; OneView, which helps marketers build a comprehensive understanding of consumer behavior; and the Marketing Intelligence Center, a dashboard that consolidates data and performance metrics. Other offerings include ClearSight, an analytics platform for customer insights, and TotalTV, which facilitates audience-based targeting across various TV formats. dataxu also produces insights through white papers and reports, and provides training and managed services for its platform users. The company serves diverse industries such as automotive, financial services, and consumer packaged goods. As a subsidiary of Roku, Inc., dataxu continues to focus on enhancing marketing effectiveness through data-driven strategies.

EnglishCentral, Inc. specializes in online English conversation solutions, providing a platform that integrates web video learning with personalized tutoring. Founded in 2008 and based in Arlington, Massachusetts, the company offers learners access to a vast library of videos across various subjects, including travel, sports, and business. Users can engage with the content through proprietary speech recognition technology that evaluates their pronunciation and syntax. The platform supports diverse learning needs by covering topics such as academic, business, and social English, while also enhancing skills in communication, grammar, and vocabulary. EnglishCentral serves a global audience of teachers and students, enabling them to improve their spoken English through interactive lessons and feedback mechanisms.